{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T11:08:39Z","timestamp":1762340919084,"version":"3.37.3"},"reference-count":99,"publisher":"American Society of Hematology","issue":"11","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2016,9,15]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Hepatitis C virus (HCV) infection is not uncommon in cancer patients. Over the past 5 years, treatment of chronic HCV infection in patients with hematologic malignancies has evolved rapidly as safe and effective direct-acting antivirals (DAAs) have become the standard-of-care treatment. Today, chronic HCV infection should not prevent a patient from receiving cancer therapy or participating in clinical trials of chemotherapy because most infected patients can achieve virologic cure. Elimination of HCV from infected cancer patients confers virologic, hepatic, and oncologic advantages. Similar to the optimal therapy for HCV-infected patients without cancer, the optimal therapy for HCV-infected patients with cancer is evolving rapidly. The choice of regimens with DAAs should be individualized after thorough assessment for potential hematologic toxic effects and drug-drug interactions. This study presents clinical scenarios of HCV-infected patients with hematologic malignancies, focusing on diagnosis, clinical and laboratory presentations, complications, and DAA therapy. An up-to-date treatment algorithm is presented.<\/jats:p>","DOI":"10.1182\/blood-2016-05-718643","type":"journal-article","created":{"date-parts":[[2016,7,22]],"date-time":"2016-07-22T02:43:40Z","timestamp":1469155420000},"page":"1449-1457","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":25,"title":["How I treat hepatitis C virus infection in patients with hematologic malignancies"],"prefix":"10.1182","volume":"128","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0814-604X","authenticated-orcid":false,"given":"Harrys A.","family":"Torres","sequence":"first","affiliation":[{"name":"Department of Infectious Diseases, Infection Control and Employee Health, The University of Texas MD Anderson Cancer Center, Houston, TX; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0581-2561","authenticated-orcid":false,"given":"George B.","family":"McDonald","sequence":"additional","affiliation":[{"name":"Gastroenterology\/Hepatology Section, Clinical Research Division, Fred Hutchinson Cancer Research Center and the University of Washington School of Medicine, Seattle, WA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"234","reference":[{"issue":"RR-4","key":"2019111902542016600_B1","first-page":"1","article-title":"Recommendations for the identification of chronic hepatitis C virus infection among persons born during 1945-1965 [published correction appears in MMWR Recomm Rep. 2012;61(43):886].","volume":"61","author":"Smith","year":"2012","journal-title":"MMWR Recomm Rep"},{"issue":"4","key":"2019111902542016600_B2","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1002\/ajh.2830460405","article-title":"Hepatitis C virus infection in patients with leukemia.","volume":"46","author":"Fujii","year":"1994","journal-title":"Am J Hematol"},{"issue":"29","key":"2019111902542016600_B3","first-page":"2925","article-title":"Reactivation of hepatitis B but not hepatitis C in patients with malignant lymphoma and immunosuppressive therapy. A prospective study in 305 patients.","volume":"46","author":"Markovic","year":"1999","journal-title":"Hepatogastroenterology"},{"issue":"1","key":"2019111902542016600_B4","first-page":"38","article-title":"Acute hepatic toxicity during cyclic chemotherapy in non Hodgkin\u2019s lymphoma.","volume":"82","author":"Faggioli","year":"1997","journal-title":"Haematologica"},{"issue":"6","key":"2019111902542016600_B5","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/S1470-2045(02)00773-8","article-title":"Reactivation of replication of hepatitis B and C viruses after immunosuppressive therapy: an unresolved issue.","volume":"3","author":"Vento","year":"2002","journal-title":"Lancet Oncol"},{"issue":"4","key":"2019111902542016600_B6","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1002\/ijc.29845","article-title":"Prevalence and association of hepatitis C virus infection with different types of lymphoma.","volume":"138","author":"Iqbal","year":"2016","journal-title":"Int J Cancer"},{"issue":"4","key":"2019111902542016600_B7","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1016\/j.jhep.2015.04.021","article-title":"Increased incidence of cancer and cancer-related mortality among persons with chronic hepatitis C infection, 2006-2010.","volume":"63","author":"Allison","year":"2015","journal-title":"J Hepatol"},{"issue":"6","key":"2019111902542016600_B8","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1053\/j.gastro.2006.09.019","article-title":"Hepatitis C and risk of lymphoma: results of the European multicenter case-control study EPILYMPH.","volume":"131","author":"Nieters","year":"2006","journal-title":"Gastroenterology"},{"issue":"1","key":"2019111902542016600_B9","doi-asserted-by":"crossref","first-page":"41","DOI":"10.6004\/jnccn.2015.0007","article-title":"Effect of hepatitis C virus infection in patients with cancer: addressing a neglected population.","volume":"13","author":"Torres","year":"2015","journal-title":"J Natl Compr Canc Netw"},{"issue":"11","key":"2019111902542016600_B10","doi-asserted-by":"crossref","first-page":"2771","DOI":"10.3748\/wjg.v20.i11.2771","article-title":"Challenges in managing hepatitis C virus infection in cancer patients.","volume":"20","author":"Borchardt","year":"2014","journal-title":"World J Gastroenterol"},{"issue":"3","key":"2019111902542016600_B11","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1038\/nrclinonc.2012.1","article-title":"Reactivation of hepatitis B virus and hepatitis C virus in patients with cancer.","volume":"9","author":"Torres","year":"2012","journal-title":"Nat Rev Clin Oncol"},{"key":"2019111902542016600_B12","unstructured":"American Association for the Study of Liver Diseases (AASLD) and the Infectious Diseases Society of America (IDSA) HCV guidance: recommendations for testing, managing, and treating hepatitis C. Available at: http:\/\/www.hcvguidelines.org. Accessed July 11, 2016"},{"issue":"4","key":"2019111902542016600_B13","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1002\/hep.22759","article-title":"Diagnosis, management, and treatment of hepatitis C: an update.","volume":"49","author":"Ghany","year":"2009","journal-title":"Hepatology"},{"issue":"2","key":"2019111902542016600_B14","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1002\/hep.25499","article-title":"Hepatitis C and non-Hodgkin lymphoma: the clinical perspective.","volume":"55","author":"Hartridge-Lambert","year":"2012","journal-title":"Hepatology"},{"issue":"6","key":"2019111902542016600_B15","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1111\/liv.12825","article-title":"Most patients with HCV-associated lymphoma present with mild liver disease: a call to revise antiviral treatment prioritization.","volume":"35","author":"Torres","year":"2015","journal-title":"Liver Int"},{"issue":"12","key":"2019111902542016600_B16","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1016\/j.amjmed.2007.06.022","article-title":"Viral elimination reduces incidence of malignant lymphoma in patients with hepatitis C.","volume":"120","author":"Kawamura","year":"2007","journal-title":"Am J Med"},{"author":"National Comprehensive Cancer Network (NCCN)","key":"2019111902542016600_B17","article-title":"Splenic Marginal Zone Lymphoma."},{"journal-title":"Leuk Lymphoma","article-title":"Development of non-Hodgkin lymphoma as a second primary cancer in hepatitis C virus-infected patients with a different primary malignancy [published online ahead of print June 27, 2016].","author":"Economides","key":"2019111902542016600_B18"},{"issue":"4","key":"2019111902542016600_B19","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1016\/j.bbmt.2015.12.010","article-title":"Hepatitis C virus infection in patients undergoing hematopoietic cell transplantation in the era of direct-acting antiviral agents.","volume":"22","author":"Kyvernitakis","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"issue":"1","key":"2019111902542016600_B20","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1002\/hep.20518","article-title":"Persistence of hepatitis C virus in patients successfully treated for chronic hepatitis C.","volume":"41","author":"Radkowski","year":"2005","journal-title":"Hepatology"},{"issue":"6","key":"2019111902542016600_B21","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1016\/j.cgh.2013.10.034","article-title":"Does chemotherapy cause viral relapse in cancer patients with hepatitis C infection successfully treated with antivirals?","volume":"12","author":"Mahale","year":"2014","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"5","key":"2019111902542016600_B22","doi-asserted-by":"crossref","first-page":"1618","DOI":"10.1182\/blood-2003-06-2145","article-title":"Long-term outcome of hepatitis C infection after bone marrow transplantation.","volume":"103","author":"Peffault de Latour","year":"2004","journal-title":"Blood"},{"issue":"11","key":"2019111902542016600_B23","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1016\/j.bbmt.2015.07.033","article-title":"Hepatitis C virus infection among hematopoietic cell transplant donors and recipients: American Society for Blood and Marrow Transplantation Task Force Recommendations.","volume":"21","author":"Torres","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"issue":"5","key":"2019111902542016600_B24","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1016\/S1473-3099(16)00118-3","article-title":"Management of viral hepatitis in patients with haematological malignancy and in patients undergoing haemopoietic stem cell transplantation: recommendations of the 5th European Conference on Infections in Leukaemia (ECIL-5).","volume":"16","author":"Mallet","year":"2016","journal-title":"Lancet Infect Dis"},{"issue":"RR08","key":"2019111902542016600_B25","first-page":"1","article-title":"Recommendations for identification and public health management of persons with chronic hepatitis B virus infection.","volume":"57","author":"Weinbaum","year":"2008","journal-title":"MMWR Recomm Rep"},{"issue":"6","key":"2019111902542016600_B26","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1016\/j.jhep.2012.07.031","article-title":"Acute exacerbation and reactivation of chronic hepatitis C virus infection in cancer patients.","volume":"57","author":"Mahale","year":"2012","journal-title":"J Hepatol"},{"issue":"7","key":"2019111902542016600_B27","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1038\/bmt.2009.56","article-title":"Severe hepatocellular injury after hematopoietic cell transplant: incidence, etiology and outcome.","volume":"44","author":"Sakai","year":"2009","journal-title":"Bone Marrow Transplant"},{"issue":"7","key":"2019111902542016600_B28","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1086\/605561","article-title":"Improving the diagnosis of acute hepatitis C virus infection with expanded viral load criteria.","volume":"49","author":"McGovern","year":"2009","journal-title":"Clin Infect Dis"},{"issue":"2","key":"2019111902542016600_B29","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1097\/PAS.0000000000000345","article-title":"Fibrosing cholestatic hepatitis C after hematopoietic cell transplantation: report of 3 fatal cases.","volume":"39","author":"Evans","year":"2015","journal-title":"Am J Surg Pathol"},{"issue":"8994","key":"2019111902542016600_B30","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/S0140-6736(96)90212-3","article-title":"Fulminant hepatitis on withdrawal of chemotherapy in carriers of hepatitis C virus.","volume":"347","author":"Vento","year":"1996","journal-title":"Lancet"},{"issue":"1","key":"2019111902542016600_B31","doi-asserted-by":"crossref","first-page":"ofv211","DOI":"10.1093\/ofid\/ofv211","article-title":"Management of multiple myeloma complicated by hepatitis C virus reactivation: the role of new antiviral therapy.","volume":"3","author":"Mahale","year":"2015","journal-title":"Open Forum Infect Dis"},{"issue":"7","key":"2019111902542016600_B32","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1038\/bmt.2016.28","article-title":"Outcomes in hepatitis C virus seropositive lymphoma and myeloma patients after autologous stem cell transplantation.","volume":"51","author":"Varma","year":"2016","journal-title":"Bone Marrow Transplant"},{"key":"2019111902542016600_B33","article-title":"Severe hepatitis C reactivation as an early complication of hematopoietic cell transplantation [published online ahead of print July 18, 2016].","author":"Oliver","year":"2016","journal-title":"Bone Marrow Transplant"},{"issue":"3","key":"2019111902542016600_B34","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.drup.2008.03.002","article-title":"CYP450 pharmacogenetics for personalizing cancer therapy.","volume":"11","author":"van Schaik","year":"2008","journal-title":"Drug Resist Updat"},{"issue":"4","key":"2019111902542016600_B35","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1016\/j.dld.2014.12.005","article-title":"Hepatocellular carcinoma as a second primary cancer in patients with chronic hepatitis C virus infection.","volume":"47","author":"Mahale","year":"2015","journal-title":"Dig Liver Dis"},{"issue":"4","key":"2019111902542016600_B36","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1007\/s10620-011-1934-1","article-title":"Effect of previous interferon treatment on outcome after curative treatment for hepatitis C virus-related hepatocellular carcinoma.","volume":"57","author":"Miyatake","year":"2012","journal-title":"Dig Dis Sci"},{"issue":"9","key":"2019111902542016600_B37","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1002\/bjs.6731","article-title":"Systematic review and meta-analysis of interferon after curative treatment of hepatocellular carcinoma in patients with viral hepatitis.","volume":"96","author":"Breitenstein","year":"2009","journal-title":"Br J Surg"},{"issue":"6","key":"2019111902542016600_B38","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1016\/j.jhep.2016.02.041","article-title":"Direct acting antivirals for decompensated cirrhosis. Efficacy and safety are now established.","volume":"64","author":"Curry","year":"2016","journal-title":"J Hepatol"},{"issue":"3","key":"2019111902542016600_B39","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1002\/hep.26972","article-title":"Evaluation for liver transplantation in adults: 2013 practice guideline by the American Association for the Study of Liver Diseases and the American Society of Transplantation.","volume":"59","author":"Martin","year":"2014","journal-title":"Hepatology"},{"issue":"suppl 1","key":"2019111902542016600_B40","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1111\/liv.13027","article-title":"Direct-acting antivirals for the treatment of hepatitis C virus infection: optimizing current IFN-free treatment and future perspectives.","volume":"36","author":"Asselah","year":"2016","journal-title":"Liver Int"},{"key":"2019111902542016600_B41","article-title":"Safety and tolerability of different antiviral regimens for chronic hepatitis c virus infection in cancer patients [abstract].","author":"Kyvernitakis","year":"2015","journal-title":"Hepatol Int"},{"author":"Mahale","key":"2019111902542016600_B42"},{"issue":"9","key":"2019111902542016600_B43","doi-asserted-by":"crossref","first-page":"3229","DOI":"10.1182\/blood.V84.9.3229.3229","article-title":"Marrow transplantation from hepatitis C virus seropositive donors: transmission rate and clinical course.","volume":"84","author":"Shuhart","year":"1994","journal-title":"Blood"},{"issue":"6","key":"2019111902542016600_B44","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1111\/tid.12306","article-title":"Hepatitis C transmission from viremic donors in hematopoietic stem cell transplant.","volume":"16","author":"Hsiao","year":"2014","journal-title":"Transpl Infect Dis"},{"issue":"9","key":"2019111902542016600_B45","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1097\/00007890-199611150-00032","article-title":"Prevention of transmission of hepatitis C virus in bone marrow transplantation by treating the donor with alpha-interferon.","volume":"62","author":"Vance","year":"1996","journal-title":"Transplantation"},{"issue":"16","key":"2019111902542016600_B46","doi-asserted-by":"crossref","first-page":"2613","DOI":"10.1182\/blood-2014-06-582122","article-title":"New nucleotide polymerase inhibitors to rapidly permit hematopoietic stem cell donation from a positive HCV-RNA donor.","volume":"124","author":"Beckerich","year":"2014","journal-title":"Blood"},{"issue":"6","key":"2019111902542016600_B47","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1002\/hep.510290609","article-title":"Hepatitis C virus infection and bone marrow transplantation: a cohort study with 10-year follow-up.","volume":"29","author":"Strasser","year":"1999","journal-title":"Hepatology"},{"article-title":"Current use and outcome of hematopoietic stem cell transplantation CIBMTR summary slides.","year":"2014","author":"Pasquini","key":"2019111902542016600_B48"},{"author":"Stirnimann","key":"2019111902542016600_B49","article-title":"Drug prescription in liver disease. In: Hawkey JC, Bosh J, Ritcher JE, Garcia-Tsao G, Chan, FKL, eds. Textbook of Clinical Gastroenterology and Hepatology."},{"issue":"12","key":"2019111902542016600_B50","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1111\/apt.12324","article-title":"Review article: prescribing medications in patients with cirrhosis - a practical guide.","volume":"37","author":"Lewis","year":"2013","journal-title":"Aliment Pharmacol Ther"},{"issue":"11","key":"2019111902542016600_B51","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1016\/S1470-2045(08)70279-1","article-title":"Part I: Liver function in oncology: biochemistry and beyond.","volume":"9","author":"Field","year":"2008","journal-title":"Lancet Oncol"},{"issue":"12","key":"2019111902542016600_B52","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1016\/S1470-2045(08)70307-3","article-title":"Part II: Liver function in oncology: towards safer chemotherapy use.","volume":"9","author":"Field","year":"2008","journal-title":"Lancet Oncol"},{"issue":"5","key":"2019111902542016600_B53","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1016\/j.bbmt.2014.01.029","article-title":"Preparative regimen dosing for hematopoietic stem cell transplantation in patients with chronic hepatic impairment: analysis of the literature and recommendations.","volume":"20","author":"Bodge","year":"2014","journal-title":"Biol Blood Marrow Transplant"},{"issue":"4","key":"2019111902542016600_B54","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1002\/hep.23533","article-title":"Hepatobiliary complications of hematopoietic cell transplantation, 40 years on.","volume":"51","author":"McDonald","year":"2010","journal-title":"Hepatology"},{"issue":"5","key":"2019111902542016600_B55","doi-asserted-by":"crossref","first-page":"2043","DOI":"10.1182\/blood-2002-06-1860","article-title":"Cyclophosphamide metabolism, liver toxicity, and mortality following hematopoietic stem cell transplantation.","volume":"101","author":"McDonald","year":"2003","journal-title":"Blood"},{"issue":"1","key":"2019111902542016600_B56","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1158\/1078-0432.273.11.1","article-title":"Accuracy, feasibility, and clinical impact of prospective Bayesian pharmacokinetically guided dosing of cyclophosphamide, thiotepa, and carboplatin in high-dose chemotherapy.","volume":"11","author":"de Jonge","year":"2005","journal-title":"Clin Cancer Res"},{"issue":"7","key":"2019111902542016600_B57","doi-asserted-by":"crossref","first-page":"2237","DOI":"10.1158\/1078-0432.CCR-03-0060","article-title":"Bayesian pharmacokinetically guided dosing of paclitaxel in patients with non-small cell lung cancer.","volume":"10","author":"de Jonge","year":"2004","journal-title":"Clin Cancer Res"},{"issue":"5","key":"2019111902542016600_B58","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1200\/JCO.1996.14.5.1504","article-title":"Escalating systemic exposure of continuous infusion topotecan in children with recurrent acute leukemia.","volume":"14","author":"Furman","year":"1996","journal-title":"J Clin Oncol"},{"issue":"1","key":"2019111902542016600_B59","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1182\/blood-2002-08-2619","article-title":"HLA-matched related hematopoietic cell transplantation for chronic-phase CML using a targeted busulfan and cyclophosphamide preparative regimen.","volume":"102","author":"Radich","year":"2003","journal-title":"Blood"},{"issue":"1","key":"2019111902542016600_B60","first-page":"31","article-title":"Graft-rejection and toxicity following bone marrow transplantation in relation to busulfan pharmacokinetics.","volume":"16","author":"Slattery","year":"1995","journal-title":"Bone Marrow Transplant"},{"issue":"6","key":"2019111902542016600_B61","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1038\/clpt.2009.27","article-title":"Personalized dosing of cyclophosphamide in the total body irradiation-cyclophosphamide conditioning regimen: a phase II trial in patients with hematologic malignancy.","volume":"85","author":"McCune","year":"2009","journal-title":"Clin Pharmacol Ther"},{"issue":"1","key":"2019111902542016600_B62","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1111\/bcp.12906","article-title":"High melphalan exposure is associated with improved overall survival in myeloma patients receiving high dose melphalan and autologous transplantation.","volume":"82","author":"Nath","year":"2016","journal-title":"Br J Clin Pharmacol"},{"key":"2019111902542016600_B63","unstructured":"US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research, and Center for Biologics Evaluation and Research Guidance for industry. Pharmacokinetics in patients with impaired hepatic function: study design, data analysis, and impact on dosing and labeling. Available at: http:\/\/www.fda.gov\/downloads\/drugs\/guidancecomplianceregulatoryinformation\/guidances\/ucm072123.pdf. 2003. Accessed July 28, 2016"},{"key":"2019111902542016600_B64","doi-asserted-by":"crossref","unstructured":"Floyd J Kerr TA Chemotherapy hepatotoxicity and dose modification in patients with liver disease. In: Drews RE, Lindor KD, eds. Waltham, MA: UpToDate. Available at: http:\/\/www.uptodate.com. 2016. Accessed July 28, 2016","DOI":"10.1097\/01.COT.0000511596.67394.37"},{"issue":"3","key":"2019111902542016600_B65","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/j.clpt.2005.05.005","article-title":"Metabolism-based cyclophosphamide dosing for hematopoietic cell transplant.","volume":"78","author":"McDonald","year":"2005","journal-title":"Clin Pharmacol Ther"},{"issue":"7","key":"2019111902542016600_B66","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1016\/j.bbmt.2013.04.005","article-title":"Cyclophosphamide followed by intravenous targeted busulfan for allogeneic hematopoietic cell transplantation: pharmacokinetics and clinical outcomes.","volume":"19","author":"Rezvani","year":"2013","journal-title":"Biol Blood Marrow Transplant"},{"issue":"1","key":"2019111902542016600_B67","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1182\/blood-2003-04-1311","article-title":"Hepatic injury after nonmyeloablative conditioning followed by allogeneic hematopoietic cell transplantation: a study of 193 patients.","volume":"103","author":"Hogan","year":"2004","journal-title":"Blood"},{"issue":"7","key":"2019111902542016600_B68","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1136\/gut.2007.131136","article-title":"A problem-oriented approach to liver disease in oncology patients.","volume":"57","author":"McDonald","year":"2008","journal-title":"Gut"},{"issue":"4","key":"2019111902542016600_B69","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/j.cld.2013.07.008","article-title":"Hepatotoxicity of antibiotics: a review and update for the clinician.","volume":"17","author":"Stine","year":"2013","journal-title":"Clin Liver Dis"},{"key":"2019111902542016600_B70","article-title":"Drug-Induced Liver Disease.","author":"Kaplowitz","year":"2013","edition":"3rd ed"},{"issue":"4","key":"2019111902542016600_B71","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1002\/jcph.14","article-title":"Population pharmacokinetics and dose optimization of mycophenolic acid in HCT recipients receiving oral mycophenolate mofetil.","volume":"53","author":"Li","year":"2013","journal-title":"J Clin Pharmacol"},{"author":"DeLeve","key":"2019111902542016600_B72"},{"issue":"9","key":"2019111902542016600_B73","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1093\/oxfordjournals.annonc.a059022","article-title":"Hepatitis C virus acute exacerbation during chemotherapy and radiotherapy for oesophageal carcinoma.","volume":"5","author":"de Pree","year":"1994","journal-title":"Ann Oncol"},{"issue":"1","key":"2019111902542016600_B74","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1001\/jama.283.1.74","article-title":"Hepatotoxicity associated with antiretroviral therapy in adults infected with human immunodeficiency virus and the role of hepatitis C or B virus infection.","volume":"283","author":"Sulkowski","year":"2000","journal-title":"JAMA"},{"issue":"1","key":"2019111902542016600_B75","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1002\/hep.1840130122","article-title":"Hepatic histological findings after transplantation for chronic hepatitis B virus infection, including a unique pattern of fibrosing cholestatic hepatitis.","volume":"13","author":"Davies","year":"1991","journal-title":"Hepatology"},{"issue":"2","key":"2019111902542016600_B76","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1002\/lt.21011","article-title":"Early histologic changes in fibrosing cholestatic hepatitis C.","volume":"13","author":"Dixon","year":"2007","journal-title":"Liver Transpl"},{"issue":"18","key":"2019111902542016600_B77","doi-asserted-by":"crossref","first-page":"2290","DOI":"10.3748\/wjg.15.2290","article-title":"Fibrosing cholestatic hepatitis following cytotoxic chemotherapy for small-cell lung cancer.","volume":"15","author":"Ceballos-Viro","year":"2009","journal-title":"World J Gastroenterol"},{"issue":"3","key":"2019111902542016600_B78","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/0753-3322(96)82604-7","article-title":"Fibrosing cholestatic hepatitis and HBV after bone marrow transplantation.","volume":"49","author":"Cooksley","year":"1995","journal-title":"Biomed Pharmacother"},{"issue":"4","key":"2019111902542016600_B79","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1002\/lt.500050417","article-title":"Fibrosing cholestatic hepatitis in renal transplant recipients with hepatitis C virus infection.","volume":"5","author":"Delladetsima","year":"1999","journal-title":"Liver Transpl Surg"},{"issue":"3","key":"2019111902542016600_B80","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/0016-5085(92)90182-X","article-title":"High-level expression of hepatitis B viral antigens in fibrosing cholestatic hepatitis.","volume":"102","author":"Lau","year":"1992","journal-title":"Gastroenterology"},{"issue":"1","key":"2019111902542016600_B81","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.intimp.2004.09.010","article-title":"Impact of mycophenolate mofetil versus azathioprine on early recurrence of hepatitis C after liver transplantation.","volume":"5","author":"Kornberg","year":"2005","journal-title":"Int Immunopharmacol"},{"issue":"11","key":"2019111902542016600_B82","doi-asserted-by":"crossref","first-page":"2002","DOI":"10.1016\/j.cgh.2015.07.018","article-title":"Severe cholestatic hepatitis C in transplant recipients: no longer a threat to graft survival.","volume":"13","author":"Giard","year":"2015","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"11","key":"2019111902542016600_B83","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1016\/j.cgh.2015.05.030","article-title":"Efficacy of sofosbuvir and daclatasvir in patients with fibrosing cholestatic hepatitis C after liver transplantation.","volume":"13","author":"Leroy","year":"2015","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"3","key":"2019111902542016600_B84","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1053\/j.gastro.2015.05.010","article-title":"Ledipasvir and sofosbuvir plus ribavirin for treatment of HCV infection in patients with advanced liver disease.","volume":"149","author":"Charlton","year":"2015","journal-title":"Gastroenterology"},{"issue":"3","key":"2019111902542016600_B85","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1053\/jhep.2002.35068","article-title":"Preemptive use of lamivudine reduces hepatitis B exacerbation after allogeneic hematopoietic cell transplantation.","volume":"36","author":"Lau","year":"2002","journal-title":"Hepatology"},{"issue":"4","key":"2019111902542016600_B86","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1097\/MOH.0b013e328353bc7d","article-title":"Immune reconstitution after hematopoietic cell transplantation.","volume":"19","author":"Bosch","year":"2012","journal-title":"Curr Opin Hematol"},{"issue":"25","key":"2019111902542016600_B87","doi-asserted-by":"crossref","first-page":"6477","DOI":"10.1182\/blood-2008-09-176594","article-title":"Acute graft-versus-host disease transiently impairs thymic output in young patients after allogeneic hematopoietic stem cell transplantation.","volume":"113","author":"Clave","year":"2009","journal-title":"Blood"},{"issue":"2","key":"2019111902542016600_B88","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1002\/hep.27920","article-title":"A clinician\u2019s guide to drug-drug interactions with direct-acting antiviral agents for the treatment of hepatitis C viral infection.","volume":"63","author":"Dick","year":"2016","journal-title":"Hepatology"},{"issue":"11","key":"2019111902542016600_B89","doi-asserted-by":"crossref","first-page":"764","DOI":"10.2146\/ajhp150704","article-title":"Genotype 1 hepatitis C virus and the pharmacist\u2019s role in treatment.","volume":"73","author":"Sebhatu","year":"2016","journal-title":"Am J Health Syst Pharm"},{"issue":"5","key":"2019111902542016600_B90","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1093\/cid\/civ973","article-title":"Drug-drug interactions with novel all oral interferon-free antiviral agents in a large real-world cohort.","volume":"62","author":"H\u00f6ner Zu Siederdissen","year":"2016","journal-title":"Clin Infect Dis"},{"issue":"suppl 1","key":"2019111902542016600_B91","doi-asserted-by":"crossref","first-page":"S12","DOI":"10.1093\/cid\/ciw220","article-title":"Pharmacologic considerations in the treatment of hepatitis C virus in persons with HIV.","volume":"63","author":"MacBrayne","year":"2016","journal-title":"Clin Infect Dis"},{"issue":"5","key":"2019111902542016600_B92","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1093\/cid\/cir930","article-title":"Hepatitis C clinic operated by infectious disease specialists at a comprehensive cancer center: help is on the way.","volume":"54","author":"Torres","year":"2012","journal-title":"Clin Infect Dis"},{"year":"2016","key":"2019111902542016600_B93","article-title":"Daklinza (daclatasvir) [prescribing information]."},{"year":"2016","key":"2019111902542016600_B94","article-title":"Epclusa (sofosbuvir and velpatasvir) [prescribing information]."},{"year":"2016","key":"2019111902542016600_B95","article-title":"Harvoni (ledipasvir and sofosbuvir) [prescribing information]."},{"year":"2016","key":"2019111902542016600_B96","article-title":"Olysio (simeprevir) [prescribing information]."},{"year":"2015","key":"2019111902542016600_B97","article-title":"Sovaldi (sofosbuvir) [prescribing information]."},{"year":"2016","key":"2019111902542016600_B98","article-title":"Viekira pak (ombitasvir p, and ritonavir tablets; dasabuvir tablets) [prescribing information]."},{"year":"2016","key":"2019111902542016600_B99","article-title":"Zepatier (elbasvir and grazoprevir) [prescribing information]."}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/128\/11\/1449\/1395120\/1449.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/128\/11\/1449\/1395120\/1449.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,3]],"date-time":"2022-07-03T16:44:53Z","timestamp":1656866693000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/128\/11\/1449\/35227\/How-I-treat-hepatitis-C-virus-infection-in"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,9,15]]},"references-count":99,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2016,9,15]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2016-05-718643","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"type":"print","value":"0006-4971"},{"type":"electronic","value":"1528-0020"}],"subject":[],"published":{"date-parts":[[2016,9,15]]}}}